Phase I study of echinomycin.

Abstract

Echinomycin was administered to patients with advanced carcinoma in escalating doses ranging from 60 to 1500 micrograms/m2 given weekly by 15-minute iv infusions for four doses, with a subsequent 2-week rest period. Dose-limiting nausea, vomiting, and anorexia associated with varying degrees of renal and hepatic dysfunction proved dose-limiting at the 1500-micrograms/m2 level. Thrombocytopenia was noted in 15% of patients receiving greater than or equal to 700 micrograms/m2 and was severe in 11% without an evident dose-response relationship. Leukopenia was rare and mild when encountered. Allergic reactions were observed. Phase II trials are feasible using a dose schedule of 1200 micrograms/m2/week X 4 weeks.

• Authors: R Pazdur, C D Haas, L H Baker, C G Leichman, D Decker
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 71 Issue 12 Pg. 1217-9 (Dec 1987) ISSN: 0361-5960 [Print] United States
• PMID: 3690532 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Intercalating Agents
• Quinoxalines
• Echinomycin

Topics

• Carcinoma (drug therapy)
• Echinomycin (adverse effects, therapeutic use)
• Humans
• Intercalating Agents (therapeutic use)
• Quinoxalines (therapeutic use)